AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...

The Times reports that AstraZeneca, the U.K.'s most valuable public company, is looking to move its listing from London to the U.S. - in a move that could strip the FTSE 100 of a firm that accounts ...

AstraZeneca’s chief executive has discussed shifting the company’s stock market listing to the US in a move that would deal a huge blow to London.

Sky's James Sillars writes that a government, struggling for authority and prioritising economic growth, can not afford to allow the FTSE 100's biggest company to leave London in favour of New York.

AstraZeneca chief executive Pascal Soriot is considering moving the company's stock exchange listing from the UK to the US – and potentially even its domicile – according to an unconfirmed media ...

--AstraZeneca's chief executive is considering moving its listing from London to the U.S. due to U.K. restrictions on medicines and pricing, The Times reports, citing unnamed sources. --Pascal ...

The company's exit from the U.K. market would spark a major index re-weighting, given AstraZeneca is the most valuable ...

Positive high-level results in trials of its baxdrostat drug to treat hypertension provided AstraZeneca shares with a ...

(Reuters) -AstraZeneca CEO Pascal Soriot is considering moving the company's stock market listing to the U.S., the Times reported on Tuesday, citing multiple sources. Soriot has privately expressed a ...

AstraZeneca, which has a market value of about 156 billion pounds ($213 billion), declined to comment. The company has for years criticised the UK business investment climate.